Evidence map›Paper›PMID 36560412›Full record

ArticleVaccines2022

Rapid Protocol Development, Study Startup and Enrolment of a Prospective Study of COVID-19 Vaccination for Patients with Cancer: A Collaborative Approach.

Amy Body, Vivienne Milch, Lynda McSorley, Luxi Lal, Elizabeth Ahern, Regina Ryan, Gayle Jones, Dorothy Keefe, Eva Segelov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Amy BodyMonash Health, Clayton, VIC 3168, Australia.ORCID 0000-0002-0601-8485
Vivienne MilchCancer Australia, Surry Hills, NSW 2010, Australia.ORCID 0000-0001-8834-0349
Lynda McSorleyMonash Health, Clayton, VIC 3168, Australia.
Luxi LalMonash Health, Clayton, VIC 3168, Australia.
Elizabeth AhernMonash Health, Clayton, VIC 3168, Australia.
Regina RyanCancer Australia, Surry Hills, NSW 2010, Australia.
Gayle JonesCancer Australia, Surry Hills, NSW 2010, Australia.
Dorothy KeefeCancer Australia, Surry Hills, NSW 2010, Australia.
Eva SegelovMonash Health, Clayton, VIC 3168, Australia.ORCID 0000-0002-4410-6144
Monash Health · AUCancer Australia · AU

Funding

Cancer Australia F21/113
6 · The paper itself

Abstract

backgroundCOVID-19 is an unprecedented global health emergency. It has been highly disruptive for patients with cancer, both due to an increased burden of severe illness and due to pressure on healthcare systems. COVID-19 vaccination has been an important public health measure for this patient group.

aimThe aim of this study was to describe the rapid design and startup of a multicentre study of COVID-19 vaccine response for vulnerable patients with cancer. Study startup: We set up a multicentre prospective observational study of COVID-19 vaccination response for Australian patients with cancer. Due to intensive collaboration between health services, the funding body and laboratories, we were able to develop a protocol and enrol the first patient within 52 days of the initial study proposal. Rapid startup was further enabled by prompt availability of funding and by high-level engagement of institutional review boards, allowing expedited review. Study enrolment: We rapidly enroled more than 500 patients, 80% within 4 months of study opening. Engagement and follow-up were maintained throughout the course of up to five serial vaccination doses.

conclusionOur study is an example of intensive collaboration inspired by the COVID-19 pandemic and may serve as an example of an agile research response to real-time public health challenges.

Indexed as

cancerCOVID-19ethics approvalprotocol developmentSARS-CoV-2study designstudy startupvaccination

Identifiers

PMID36560412
PMCPMC9785949
OpenAlexW4310037818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.